Not So Different: A Podcast from The Center for Biosimilars
Not So Different: a Podcast from The Center for Biosimilars
158 episodes
1 month ago
In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of Accessible Medicines tackle the FDA's recent draft guidance on clinical efficacy testing and interchangeability for biosimilars, addressing some of the confusion around the new announcement and remaining action items for the agency.
All content for Not So Different: A Podcast from The Center for Biosimilars is the property of Not So Different: a Podcast from The Center for Biosimilars and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of Accessible Medicines tackle the FDA's recent draft guidance on clinical efficacy testing and interchangeability for biosimilars, addressing some of the confusion around the new announcement and remaining action items for the agency.
S6 Ep37: Biosimilars Policy Roundup for September 2024—Podcast Edition
Not So Different: A Podcast from The Center for Biosimilars
7 minutes
1 year ago
S6 Ep37: Biosimilars Policy Roundup for September 2024—Podcast Edition
On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Not So Different: A Podcast from The Center for Biosimilars
In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of Accessible Medicines tackle the FDA's recent draft guidance on clinical efficacy testing and interchangeability for biosimilars, addressing some of the confusion around the new announcement and remaining action items for the agency.
